Driven Brands (DRVN) FY 2025 Conference September 04, 2025 01:50 PM ET Speaker1All right. Good afternoon, everyone. Thank you for joining us at the Goldman Sachs 32nd Annual Global Retailing Conference. My name is Mark Jordan. I'm an analyst here at Goldman Sachs. It's my pleasure to introduce Driven Brands and to moderate our fireside chat. We have with us today Daniel Rivera, President and CEO, and Mike Diamond, Executive Vice President and Chief Financial Officer. Daniel, Mike, it's a pleasure to have yo ...

Macy’s (M) FY 2025 Conference September 04, 2025 01:50 PM ET Speaker2Good afternoon and welcome to this next session of the Goldman Sachs 32nd Annual Global Retailing Conference. My name is Brooke Roach, and I cover the apparel, soft lines, and branded consumer goods here at GS. I'm thrilled to introduce our next session with Macy's. Here today representing Macy's is Tony Spring, Chairman and CEO, and Tom Edwards, COO and CFO. Welcome, Tony, and welcome, Tom.Speaker1Thank you, Brooke. Great to be with you.S ...

Soleno Therapeutics (SLNO) FY 2025 Conference September 04, 2025 01:30 PM ET Company ParticipantsAnish Bhatnagar - CEO & ChairmanJim Mackaness - CFOConference Call ParticipantsDerek Archila - MD, Co-Head - Therapeutics Research & Senior Biotechnology AnalystDerek ArchilaAll right, everyone, I think we'll get started here with our next fireside discussion. My name is Derek Archila. I'm the Senior Biotech Analyst here at Wells Fargo. Looking forward to our next discussion here with Soleno Therapeutics from th ...

Freshpet (FRPT) FY 2025 Conference September 04, 2025 01:30 PM ET Company ParticipantsAndrew Lazar - Managing DirectorBilly Cyr - CEO & DirectorTodd Cunfer - CFOAndrew LazarPerfect. Okay, everybody. Thanks for hanging in there on day three. We're excited to welcome back Freshpet with us today. Again, with us are CEO Billy Cyr and Chief Financial Officer Todd Cunfer. Thanks so much for joining.Billy CyrGlad to be here.Andrew LazarMaybe we start off with, as we've heard over the past couple of days, right? If ...

Halozyme Therapeutics (HALO) FY 2025 Conference September 04, 2025 01:30 PM ET Company ParticipantsHelen Torley - President, CEO & DirectorMohit Bansal - MD & Co-Head of Therapeutics ResearchMohit BansalAwesome. Thank you very much for joining us today. This is not quite the post-lunch. There's one after the post-lunch session. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo, and I'm joined by Dr. Helen Torley. Helen has been coming here longer than I have been here. Thank you ...

Masimo (MASI) FY 2025 Conference September 04, 2025 01:30 PM ET Company ParticipantsMicah Young - EVP & CFOKatie Szyman - CEO & DirectorConference Call ParticipantsVik Chopra - Equity Research AnalystVik ChopraGood afternoon, everyone. My name is Vivek Chopra. I am on the Medical Device Equity Research team here at Wells Fargo. I'm happy to announce management from Masimo for this session. Joining us for the company are Katie Szyman, CEO, and Micah Young, VP and CFO. Thank you both for being here.Micah Youn ...

Halozyme Therapeutics (HALO) FY 2025 Conference September 04, 2025 01:30 PM ET Speaker1Awesome. Thank you very much for joining us today. This is not quite the post-lunch. There's one after the post-lunch session. My name is Mohit Bansal. I'm one of the biopharma analysts here at Wells Fargo, and I'm joined by Dr. Helen Torley. Helen has been coming here longer than I have been here. Thank you very much for being consistent with coming to this conference.Speaker0Yeah, we appreciate it, Mohit. That was a gre ...

Financial Data and Key Metrics Changes - The company has adjusted its net dollar retention expectations from 103% to 93% due to pricing pressure and client behavior changes during the Egnyte migration [15][19][22] - The average sales benchmark (ASB) has shifted to the lower end of the range, now between $300,000 and $700,000, primarily due to tighter scoping rather than lower gross margins, which remain strong at over 80% [27][29] Business Line Data and Key Metrics Changes - The company has added 22 new platform clients since the beginning of the year, bringing the total to 152 platform clients [23] - The focus for cross-selling is on adjacent applications, particularly in the finance category, which offers clear near-term ROI for clients [31][32] Market Data and Key Metrics Changes - Many clients are currently using the 2026 budgeting cycle to reassess their needs and strategies in light of recent Medicaid cuts and funding changes [20] - The company is experiencing a stronger start to Q3 compared to typical quiet quarters, indicating potential recovery in client engagement [18] Company Strategy and Development Direction - The company is focusing on leveraging its existing client relationships to roll out AI capabilities without requiring new contracts, capitalizing on its incumbency advantage [52] - There is a strategic shift towards tech-led solutions, with a goal to increase the proportion of revenue from technology services compared to professional services [42] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that the current macro environment is challenging, particularly for not-for-profit health systems, which are slower to adapt to significant funding cuts [16] - The company expects the headwind to dollar-based retention to be a near-term issue, with a return to over 100% retention anticipated by 2027 [26][22] Other Important Information - The company has identified over $40 million in savings from a recent restructuring, which will positively impact EBITDA in the upcoming quarters [49][54] - There is no anticipated further M&A activity in the near to mid-term, as the company focuses on digesting recent acquisitions and maximizing cross-sell opportunities [58] Q&A Session Summary Question: What is the impact of the Egnyte migration on dollar-based retention? - Management explained that the migration has led to a reduction in dollar-based retention due to clients opting for immediate savings rather than cross-selling opportunities [15][19] Question: How is the company addressing the tighter scoping in sales? - The company noted that while scoping is tighter, it has maintained good gross margins and is still signing meaningful business [29][30] Question: What is the company's strategy regarding professional services? - Management clarified that while they are reducing reliance on professional services, they still see value in providing deep domain expertise where necessary [39][42] Question: How is AI influencing the company's operations? - The company is increasingly using AI in R&D, which is expected to provide significant operating leverage and improve efficiency [48][49] Question: What are the capital strategy priorities moving forward? - The focus is on achieving meaningful free cash flow in 2026, with plans for share repurchase and debt repayment as primary uses of capital [57][58]

Beam Therapeutics (BEAM) FY 2025 Conference September 04, 2025 01:30 PM ET Speaker0Thanks, everyone, for being here. My name is Yann Anzou. I'm one of the biotech analysts here at Wells Fargo. It is my great pleasure to introduce our next fireside chat. We are privileged to have the Beam Therapeutics team with us. Here on stage are John Evans, CEO, and Pino Ciaramella, President of the company. Thank you, Pino, and thank you, John, for being here.Speaker2Thanks for having us.Speaker0Great. I was wondering i ...

Masimo (MASI) FY 2025 Conference September 04, 2025 01:30 PM ET Speaker0Good afternoon, everyone. My name is Vivek Chopra. I am on the Medical Device Equity Research team here at Wells Fargo. I'm happy to announce management from Masimo for this session. Joining us for the company are Katie Szyman, CEO, and Micah Young, VP and CFO. Thank you both for being here.Speaker2Thank you, Vivek.Thank you.Speaker0Katie, maybe starting off with you, a few big-picture questions. You've been CEO since the beginning of t ...